By Thomas Martinuzzo
Director, Business Development, Science and Engineering, Univalor

I recently had the chance to attend TechConnect World 2013. This annual gathering of technological innovators took place in Washington, D.C., from May 12 to 16. This was the seventh time I had participated in this event, and I have to say that I think it is one of the best engineering conferences that exists. Focused on the advancement of technology in the fields of engineering, nanotechnology, biotechnology and clean technology, TechConnect World is the only international forum that I know of where large companies and venture capital investors can share their technological innovation needs, and where people holding the rights to innovative technologies can present their products to a discerning public. However, not everybody can present at TechConnect World. In 2013, only 20% of the technologies submitted to the selection committee were presented. This means the event brings together the top innovators in the industry.


Montreal firm Photon etc., a specialist in optics and photonics instrumentation, collaborates regularly with researchers from the Université de Montréal, and for good reason: until recently, its offices were in the university’s J.-Armand Bombardier building, which houses an incubator and laboratories dedicated to nanoscience and nanotechnology. This is where Photon etc. and Professor Richard Martel, a specialist in nanotechnology, began their collaboration.


When people with serious or chronic illnesses don’t integrate medication into their routine, the consequences can be harmful, even devastating. If they don’t take their medication on a rigorous schedule, they may reduce the chances of successful treatment and, in some cases, increase drug resistance and allow the disease to gain strength.


Press Release
For Immediate Release

Montreal, May 21, 2013 - AmorChem and Univalor are proud to announce the closing of a reinvestment in the project led by Dr. Nabil Seidah (Institut de recherches cliniques de Montréal). This project, launched in March 2012, is focused on finding drugs which can interact with PCSK9, a well-known target which pharmaceutical companies are pursuing in the treatment of hypercholesterolemia.